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Abstract Our previous paper (Wilkinson et al, 2016) used high-resolution cryo-electron
microscopy to solve the structure of the Escherichia coli RecBCD complex, which acts in both the
repair of double-stranded DNA breaks and the degradation of bacteriophage DNA. To counteract
the latter activity, bacteriophage l encodes a small protein inhibitor called Gam that binds to
RecBCD and inactivates the complex. Here, we show that Gam inhibits RecBCD by competing at
the DNA-binding site. The interaction surface is extensive and involves molecular mimicry of the
DNA substrate. We also show that expression of Gam in E. coli or Klebsiella pneumoniae increases
sensitivity to fluoroquinolones; antibacterials that kill cells by inhibiting topoisomerases and
inducing double-stranded DNA breaks. Furthermore, fluoroquinolone-resistance in K. pneumoniae
clinical isolates is reversed by expression of Gam. Together, our data explain the synthetic lethality
observed between topoisomerase-induced DNA breaks and the RecBCD gene products,
suggesting a new co-antibacterial strategy.
DOI: 10.7554/eLife.22963.001
Introduction
In bacterial cells, the related AddAB and RecBCD enzymes are helicase-nuclease complexes respon-
sible for initiating homologous recombination from double-stranded DNA breaks (DSBs). This activ-
ity underpins many key DNA transactions including DSB repair, phage restriction, and conjugal or
transductional recombination (Dillingham and Kowalczykowski, 2008; Wigley, 2013).
Several observations suggest that selective inhibition of AddAB/RecBCD could be useful in bio-
technology and medical applications. For example, they are important for the infectivity and patho-
genicity of bacteria that need to resist oxidative and nitrosative attack from neutrophils and
macrophages (Amundsen et al., 2008; Darrigo et al., 2016; Amundsen et al., 2009; Cano et al.,
2002). They protect cells from antibacterials that cause DSBs, such as ciprofloxacin, because they
afford a basal level of protection against such damage (Amundsen et al., 2009; Henderson and
Kreuzer, 2015; Gonza´lez-Soltero et al., 2015; Tamae et al., 2008; McDaniel et al., 1978). More-
over, the repair of such DSBs stimulates mutagenesis and recombination via both SOS-dependent
and –independent mechanisms which may enhance the acquisition of antibacterial resistance
(Lo´pez et al., 2007; Cirz et al., 2005). Finally, RecBCD activity interferes with RecET- and Redab-
mediated ‘recombineering’, and so efficient bacterial genome engineering may require a recBC
genetic background (Court et al., 2002; Datta et al., 2008; Zhang et al., 1998; Muyrers et al.,
1999).
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Many phage-encoded proteins manipulate host cell metabolism in order to promote phage repli-
cation and lysis (Liu et al., 2004). For example, phage l Gam is a potent inhibitor of the Escherichia
coli RecBCD complex that helps to protect the phage DNA from degradation (Sakaki et al., 1973;
Murphy, 1991). In this work, we present the structure of Gam bound to RecBCD unveiling an inhibi-
tion mechanism based on protein mimicry of a DSB. We also show that E. coli and Klebsiella pneu-
moniae cells expressing Gam are hypersensitive to ciprofloxacin. Moreover, inhibition of RecBCD
can restore susceptibility to laboratory-selected mutants and clinical isolates of K. pneumoniae that
are fluoroquinolone resistant. More generally, we argue that the study of other phage-encoded
DNA mimics will help to identify novel antibiotic targets and new mechanisms for target inhibition.
Results
Gam interacts with the DNA-binding site of RecBCD
The Gam protein exists in two isoforms called GamL and GamS which differ in length (Sakaki et al.,
1973). Previous work has shown that GamS inhibits RecBCD by competing with DNA binding
(Court et al., 2007; Murphy, 2007). The structure we present here, of the GamS dimer complexed
with RecBCD, was determined by cryo-electron microscopy at 3.8 A˚ resolution (Figure 1, Figure 1—
source data 1, Figure 1—figure supplements 1 and 2, Video 1). It reveals that the GamS protein
does indeed act as a steric block to the binding of DNA (Figure 1). The interaction with the duplex
DNA-binding ‘arm’ of the RecB subunit is extensive and overlaps completely with that of the duplex
DNA binding site (Figure 1 and Video 2). Furthermore, one of the long N-terminal helical extensions
of GamS inserts deeply into RecBCD. It occupies a channel that normally accommodates the nascent
3’-ssDNA tail bound to the RecB helicase subunit, increasing the extent of the steric block (Figure 1).
Although the structure of the RecBCD complex is closest to that of the initiation complex
(Singleton et al., 2004) it responds to the binding of Gam by small changes in conformation. The 2B
and C-terminal domains of the RecC subunit together with the 2B domain of RecB move as a unit
away from the RecB helicase domains. The RecD subunit is also much more flexible.
The crystal structure of the GamS protein alone (Court et al., 2007) revealed a pattern of nega-
tive charges on the surface that mimicked a DNA duplex, suggesting that molecular mimicry might
be involved in binding. Consistent with this idea, a series of acidic side chains on Gam are located in
positions equivalent to the phosphates of the DNA backbone and interact with many of the same
residues on the RecBCD surface (Figure 2 and Figure 2—figure supplement 1). However, the inter-
action of RecBCD with GamS is much more extensive than with duplex DNA (Figure 2A and B). The
interactions of the N-terminal helix with the ssDNA channel are less similar to those involved in
ssDNA binding although there is some conservation of hydrophobic contacts across the site
(Figure 2C and D and Figure 2—figure supplement 2). Instead, the main component of the interac-
tion is simply a steric block; the helix makes a snug fit in the channel involving many more contacts
than the equivalent contacts with ssDNA (Video 3). Overall, the interaction surface involves many
contacts and covers approximately 2500 A˚2 which explains why the interaction between the proteins
is so tight (Court et al., 2007; Murphy, 2007).
Escherichia coli cells expressing Gam are hypersensitive to ciprofloxacin
Quinolone antibacterials target DNA gyrase and topoisomerase IV and kill cells by stabilising cova-
lent topoisomerase-DNA adducts to produce DSBs. Based on the sensitivity of recBC cells to quino-
lones (Henderson and Kreuzer, 2015; Gonza´lez-Soltero et al., 2015; Tamae et al., 2008;
McDaniel et al., 1978) and the well-characterised role of RecBCD in the repair of DSBs
(Dillingham and Kowalczykowski, 2008), we hypothesised that expression of Gam would potenti-
ate the killing effects of ciprofloxacin. To test this hypothesis, we engineered pBAD plasmids to
express the two isoforms of Gam (GamL and GamS) from an arabinose-inducible promoter. In the
absence of ciprofloxacin, expression of Gam had no apparent effect on the viability of E. coli
MG1655 (Figure 3—figure supplement 1). We next compared the ciprofloxacin minimum inhibitory
concentration (MIC) against E. coli cells either expressing Gam or containing an empty vector con-
struct. In broth culture, expression of either GamS or GamL reduced the MIC by approximately four-
fold compared to the control, and equivalent results were obtained using spot tests on agar plates
(Figure 3A and Figure 3—figure supplement 1). The MIC potentiation effect was dependent on
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arabinose (Figure 3—figure supplement 1) and specific for quinolone-induced DSBs; equivalent
experiments measuring the MIC for ampicillin showed no effect of Gam (data not shown). These
experiments demonstrate, at the biochemical level, the synthetic lethality observed between topo-
isomerase malfunction and RecBCD in gene knockout studies (Tamae et al., 2008).
Figure 1. The overall structure of the RecBCD/Gam complex. (A) Surface representation of the electron density with a ribbon representation of the
RecBCD subunits and the GamS protein dimer. (B) Cut away of the molecular surface of the RecBCD part of the model with the GamS dimer overlaid
showing how the protein enters and fills the channel normally occupied by the 3’ssDNA tail. (C) The same view with the electron density for the GamS
dimer overlaid.
DOI: 10.7554/eLife.22963.002
The following source data and figure supplements are available for figure 1:
Source data 1. EM data statistics and Final model.
DOI: 10.7554/eLife.22963.003
Figure supplement 1. Electron microscopy information.
DOI: 10.7554/eLife.22963.004
Figure supplement 2. Representation of the local resolution of the GamS1 N-terminal helix for the deposited map compared to the same region in the
maps of each of the three sub-classes.
DOI: 10.7554/eLife.22963.005
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Inhibition of DSB repair reverses
fluoroquinolone resistance in K.
pneumoniae, including clinical
isolates
K. pneumoniae is an important opportunistic
human pathogen that causes a variety of infec-
tions and is of increasing concern due to the
recent emergence of antibiotic resistant and
hypervirulent strains (Paczosa and Mecsas,
2016). To test whether Gam expression
increased the susceptibility of wild type K. pneu-
moniae to fluoroquinolones, we used disc suscep-
tibility testing to four different fluoroquinolones.
These are standardised assays based on inhibi-
tion zone diameter values defined by the CLSI
(CLSI, 2015) which classify bacterial strains as
either resistant, or not resistant, to fluoroquino-
lones based on the expected efficacy of the drug
in a clinical context. Five strains were used: the
wild-type strain Ecl8, two laboratory-selected
Ecl8 mutant derivatives having sequentially
reduced ciprofloxacin susceptibility, and two K. pneumoniae clinical isolates. Ecl8, and the single-
step reduced susceptibility mutant Ecl8-CIP-M1 are not clinically resistant to any of the four test fluo-
roquinolones regardless of Gam expression, although cells containing the phage protein are signifi-
cantly more susceptible (i.e. the inhibition zone diameters are greater in all cases) confirming
fluoroquinolone potentiation by Gam in this species (Figure 3B and Table 1). The two-step mutant
ECl8-CIP-M2 and clinical isolate R16 are classified as clinically resistant to all four test fluoroquino-
lones; isolate R20 is resistant to three of them. In all cases, expression of GamL increases fluoroquin-
olone susceptibility to a level that reverses clinical resistance. Whilst GamS generally had a smaller
effect than GamL, it still reversed resistance in all but the least susceptible clinical isolate, R16
(Table 1).
Discussion
The recent work of DuBow and colleagues has elegantly demonstrated the potential for novel anti-
bacterial discovery through the characterisation of bacteriophage:host interactions (Liu et al., 2004).
Indeed, phage have evolved a wide variety of
strategies to repurpose host cell functions for
their own benefit, including inhibition of key bac-
terial proteins. These include many examples of
proteins that target DNA replication, recombina-
tion and repair factors, which often share the pri-
mary structure characteristics of DNA mimic
proteins (Wang et al., 2014). Characterisation of
DNA mimic proteins provides an attractive route
towards the identification and validation of novel
antibiotic targets, because bacterial DNA trans-
actions are not only crucial for survival but are
structurally orthogonal to their eukaryotic coun-
terparts (Robinson et al., 2012). Moreover, the
systematic analysis of the antibiotic sensitivity of
single gene knockouts in E. coli highlights the
potential of targeting DNA binding proteins as
part of ‘co-antibacterial’ strategies to potentiate
the effects of existing drugs (Tamae et al.,
2008).
Video 1. Electron density map. A region of the
electron density is shown in the location of the
N-terminal helix of the Gam subunit that is located in
the ssDNA binding site of the RecB subunit. Side chain
density is clearly visible.
DOI: 10.7554/eLife.22963.006
Video 2. Overlay of the DNA substrate and the GamS
dimer bound to RecBCD.
DOI: 10.7554/eLife.22963.007
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Figure 2. Comparison of the RecBCD/Gam and RecBCD/DNA interfaces. (A) Cartoon representation of contacts between RecBCD and the duplex
portion of bound DNA. RecB is in orange and RecC in cyan in all panels. Interactions involving main chain atoms are denoted as m/c. (B) The same
interface but with the GamS dimer (shown in magenta and purple). The interaction is much more extensive than with DNA but contacts in common are
Figure 2 continued on next page
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In this work, we determined the structural basis for inhibition of the RecBCD complex by the
phage-encoded DNA mimic Gam, and exploited this interaction to show that inhibition of host cell
DSB repair is a useful co-antibacterial strategy alongside quinolone drugs. GamL reversed resistance
to all four tested fluoroquinolones in clinical isolates of multi-drug resistant K. pneumoniae, a human
pathogen, as defined by an assay validated to predict clinical efficacy of antibacterial drugs
(CLSI, 2015). Our data show that the Gam protein works by blocking the DNA binding site, partly
by imitating both the single- and double-stranded portions of broken DNA. Gam has also been
reported to interact with the SbcCD complex, another nuclease implicated in DNA repair
(Kulkarni and Stahl, 1989). However, inhibition of SbcCD is unlikely to contribute to the antibacte-
rial potentiation effect observed here, because cells lacking SbcCD activity are not sensitive to cipro-
floxacin (Henderson and Kreuzer, 2015; Aedo and Tse-Dinh, 2013; Liu et al., 2010). DNA mimicry
has been observed previously for phage-encoded proteins that target type I restriction endonu-
cleases and glycosylases (Kennaway et al., 2009; Ban˜os-Sanz et al., 2013; Cole et al., 2013) and it
may be a common mechanism for bacteriophages to modulate DNA replication and repair in their
hosts. Bacteriophage P22 codes for another, distinctive RecBCD inhibitor called Abc2 but this oper-
ates by a poorly-characterised mechanism (Murphy, 2000). Moreover, a small molecule inhibitor of
AddAB/RecBCD (ML328) has recently been developed (Bannister et al., 2010). It will be of great
interest to understand the inhibitory mechanisms of these molecules, expanding our understanding
of how we can control bacterial DNA repair and, potentially, exploit this knowledge to combat anti-
bacterial resistance.
Materials and methods
Cloning of the bacteriophage l Gam protein
For over-expression in E. coli, the gene encoding bacteriophage lambda GamS, corresponding to
residues 41–138 of the full-length Gam protein, was synthesised with codon optimisation for E.coli
expression (GeneArt, Thermo Fisher, Waltham, MA, USA). GamS was cloned into pET22b, between
NdeI and BamHI, using In-Fusion cloning. For flu-
oroquinolone potentiation studies, the genes
encoding GamS and full length GamL were
cloned into the pBAD322K plasmid (which repli-
cates in both E. coli and K. pneumoniae) under
the control of an arabinose-inducible promoter
(a gift from Prof. John Cronan, University of Illi-
nois [Cronan, 2006]) using the NcoI and HindIII
restriction sites. All plasmid sequences were veri-
fied by direct DNA sequencing.
Expression and purification of the
RecBCD-Gam complex
GamS protein was over-expressed using the
pET22b construct in BL21 (DE3) cells with 4 hr
induction at 27˚C. The purification procedure for
Figure 2 continued
shown in bold. (C) Contacts between RecBCD and the ssDNA tails of DNA. (D) The same interface but with the GamS dimer. Again the interactions are
much more extensive but still include several residues in common (shown in bold).
DOI: 10.7554/eLife.22963.008
The following figure supplements are available for figure 2:
Figure supplement 1. Space filling representations of the bound DNA substrate and GamS dimer with negative charges coloured in red.
DOI: 10.7554/eLife.22963.009
Figure supplement 2. Aspects of molecular mimicry are shown in a comparison of the interactions in RecBCD/DNA complex with that of the RecBCD/
Gam complex in the region of the 3’-tail of the DNA substrate.
DOI: 10.7554/eLife.22963.010
Video 3. Details of the interactions between the
N-terminal helix of Gam and the RecB subunit.
DOI: 10.7554/eLife.22963.011
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Figure 3. Inhibition of bacterial DSB repair potentiates fluoroquinolone antibiotics. (A) Ciprofloxacin minimum
inhibitory concentration (MIC) assay against E. coli MG1655 cells in the presence or absence of Gam isoforms as
indicated. Experiments were performed as described in the Materials and methods in the presence of arabinose
to induce expression of the small or large isoforms of Gam. Control experiments were performed under identical
conditions with the empty pBADK expression vector. (B) Disc susceptibility assays are standardised tests that
quantify antibacterial susceptibility in terms of an inhibition zone diameter, and also classify bacterial strains as
either resistant, or not resistant, to antibacterial agents based on expected drug efficacy in a clinical setting. The
experiments were performed and interpreted in accordance with CLSI guidelines (CLSI, 2015) with a range of
fluoroquinolones (CIP; ciprofloxacin, OFL; ofloxacin, NOR; norfloxacin, LEV, levoxofloxacin). Illustrative results for
wild type K. pneumoniae (Ecl8) and a resistant strain (Ecl8-CIP-M2) are shown using the GamL isoform. Note that
the magnification of the plates is different for the two strains as is apparent from the disc sizes. The inhibition zone
diameters for all strains, with both GamL and GamS, are summarised in Table 1.
Figure 3 continued on next page
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GamS was as described (Court et al., 2007). As observed previously, GamS purifies as a dimer. E.
coli RecBCD complex was expressed and purified as described (Wilkinson et al., 2016). A 2:1 molar
excess of dimeric GamS was incubated with RecBCD for 15 min at room temperature prior to size-
exclusion chromatography with a Superdex 75 10/300 GL column, to separate free GamS. The buffer
used contained: 25 mM Tris pH 7.5, 50 mM NaCl and 0.5 mM TCEP (pH 7.0). The peak fractions
were pooled and concentrated to 1.4 mg/ml using Vivaspin 30 KDa molecular weight cut-off centrif-
ugal concentrators.
Cryo-electron microscopy grid preparation and data collection
Thinned C-flat 1  1 mm holey carbon film grids were prepared as described (Wilkinson et al.,
2016). Grids were thinned using a total of 3 min of glow discharge (in 30 s steps), left for two weeks
and then treated using a 1 mM solution of Amphipol A8-35. Sample (3 mL) was evenly applied to the
grid before blotting and freezing in liquid ethane using a Vitrobot Mark IV (FEI). For blotting, a rela-
tive blot force of  4 for 1 s at 4˚C was used. Data were collected using a Titan Krios I microscope
Figure 3 continued
DOI: 10.7554/eLife.22963.012
The following figure supplement is available for figure 3:
Figure supplement 1. Spot tests for ciprofloxacin sensitivity on agar plates.
DOI: 10.7554/eLife.22963.013
Table 1. Disc susceptibility assay for K. pneumoniae Ecl8wt, derived mutants and clinical isolates expressing GamL or GamS from
pBADK. The disc susceptibility assay were performed according to the CLSI protocol (CLSI, 2015) using Mueller-Hinton agar with
0.2% (w/v) arabinose to stimulate expression of cloned genes (in bracket) and 30 mg/L kanamycin to select for the pBADK plasmids.
Resistance breakpoints are as set by the CLSI (CLSI, 2015). Values shaded designate resistance. Values reported are the means of
three repetitions rounded to the nearest integer.
K. pneumoniae strains Diameter of growth inhibition zone (mm) around fluoroquinolone disc
Fluoroquinolone (mg in disc)
Ciprofloxacin (5) Levofloxacin (5) Norfloxacin (10) Ofloxacin (5)
Ecl8wt pBADK (Control) 34 32 30 30
Ecl8wt pBADK (GamL) 40 37 37 37
Ecl8wt pBADK (GamS) 46 42 41 39
Ecl8-CIP- M1 pBADK (Control) 24 21 20 19
Ecl8-CIP-M1 pBADK (GamL) 31 27 24 24
Ecl8-CIP-M1 pBADK (GamS) 28 27 25 25
Ecl8-CIP-M2 pBADK (Control) 14 12 11 8
Ecl8-CIP-M2 pBADK (GamL) 21 17 16 14
Ecl8-CIP-M2 pBADK (GamS) 21 18 16 14
R16 pBADK (Control) 8 8 8 6
R16 pBADK (GamL) 17 16 16 16
R16 pBADK (GamS) 15 15 15 12
R20 pBADK (Control) 15 13 14 11
R20 pBADK (GamL) 20 19 19 15
R20 pBADK (GamS) 18 17 17 15
DOI: 10.7554/eLife.22963.014
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operated at 300 KV at eBIC, Diamond, UK. Zero loss energy images were collected automatically
using EPU (FEI) on a Gatan K2-Summit detector in counting mode with a pixel size corresponding to
1.34 A˚ at the specimen. A total of 358 images were collected with a nominal defocus range of  1.2
to  2.4 mm. Each image consisted of a movie stack of 25 frames with a total dose of 36 electrons/A˚2
over 10 s corresponding to a dose rate of 6.5 electrons/pixel/s.
Data processing
All 25 movie frames for each image stack were aligned and summed using Motioncorr (Li et al.,
2013) prior to processing with Relion1.4 (Scheres, 2016). The actual defocus and other contrast
transfer function (CTF) parameters for each summed movie stack were determined using Gctf
(Zhang, 2016). Outlying micrographs were removed based on a number of criteria, leaving 334
images with Thon rings extending to an estimated resolution range from 6.2–2.8 A˚ (mean of 3.4 A˚)
and defocus range between  0.6 to  2.9 mm. The program Gautomatch (Urnavicius et al., 2015)
was used for automated, template-free particle picking with a circular particle diameter of 140 A˚,
picking 134,124 particles. Initially, reference-free 2D classification was used to remove poor particles
from autopicking, leaving 122,796 particles judged to represent potential protein complexes. These
were subjected to 3D classification using the RecBCD:DNA crystal structure (PDB:1 W36)
(Singleton et al., 2004), low-pass filtered to 45 A˚, as a starting model. All four classes generated
contained complexes of GamS with RecBCD although with different occupancy of the RecB nuclease
and RecD 2A/2B domains. All particles were initially kept together for more robust classification after
correcting for single-particle movement and per-frame radiation damage in particle polishing. 3D
refinement of the 122,896 particles yielded a map with a resolution of 4.4 A˚ before masking (as esti-
mated by the ‘gold-standard’ Fourier Shell Correlation (FSC) at the 0.143 cut-off criterion). After
application of an auto-generated mask in Relion, the resolution of the map was 4.0 A˚. Particle polish-
ing improved the masked resolution to 3.8 A˚.
At this point 3D classification without alignment (Scheres, 2016) was used to separate the differ-
ent conformations within the data. The data were split into 10 classes with the majority (82%) falling
into three major distinct classes. There were 30% of the particles in a class that lacked density for
the RecB nuclease. The other two classes both represented the full complex with a similar spread of
views but, when refined separately, showed slightly different conformations of a block of domains
including the RecB 2B domain, part of the RecC CTD and the RecD 2A/2B domains. Since the GamS
and surrounding structure was consistent for all three classes, they were summed for the final map
at 3.8 A˚. The final applied b-factor for sharpening used in post-processing was  70 A˚2 with the
resulting FSC plot shown in Figure 1—figure supplement 1.
Model building and refinement
Scripts for map conversion, cell matching and refinement in Refmac were kindly provided by Garib
Murshudov (MRC-LMB). The recent cryo-EM structure of RecBCD in complex with DNA (PDB: 5LD2)
(Wilkinson et al., 2016), and the crystal structure of GamS (PDB: 2UUZ) (Court et al., 2007), were
used as starting models for global docking in Chimera (Pettersen et al., 2004). Jelly-body Refmac
refinement was used to correct for conformational changes in the model from the template struc-
tures. The entire model was carefully edited and fit using real-space refinement in Coot
(Emsley et al., 2010) with occasional jelly-body refinement with Refmac, monitoring geometry statis-
tics throughout. Near the end, phenix.real_space_refine (Afonine et al., 2013) was used to generate
the final model, assign two group B-factors per residue and model statistics (see Figure 1—source
data 1).
Bacterial strains and fluoroquinolone sensitivity tests
Fluoroquinolone sensitivity was tested in E. coli MG1655 and five different strains of K. pneumoniae;
wild-type isolate Ecl8 (a fully susceptible strain (Forage and Lin, 1982) and a gift from Dr T.
Schneiders, University of Edinburgh); Ecl8-CIP-M1, a mutant derivative selected for growth on LB
agar containing 30 ng/mL of ciprofloxacin following plating of 100 mL of an overnight culture of Ecl8;
Ecl8-CIP-M2, a mutant derivative selected for growth on LB agar containing 4 mg/mL of ciprofloxacin
following plating of 100 mL of an overnight culture of Ecl8-CIP-M1; clinical isolates R16 and R20
selected because of their reduced ciprofloxacin susceptibility (cultured from the blood of patients
Wilkinson et al. eLife 2016;5:e22963. DOI: 10.7554/eLife.22963 9 of 12
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being treated at Southmead Hospital, Bristol and a gift of Prof A. P. MacGowan). Minimum inhibi-
tory concentration (MIC) assays were performed as described previously with some modifications
(Wiegand et al., 2008). Ciprofloxacin stocks of 4 mg/ml were made by dissolving in 0.1M HCl. Anti-
biotic serial dilutions were made in Mueller Hinton broth (MHB). For assays using E. coli, cells were
grown in the absence of the inducer arabinose at 37˚C to reach stationary phase. Cells were then
diluted in MHB to OD600 ~10
 4 or an approximate cell count of 105 cfu.ml 1 within each well of a 96
well plate. The plates were incubated at 37˚C for 18 hr. Where appropriate, the wells were supple-
mented with kanamycin (50 mg/ml), arabinose (1% w/v), and various antibiotics at the indicated con-
centrations. For K. pneumoniae, antibiotic susceptibility disc tests followed the CLSI protocol
(CLSI, 2015). Media were supplemented with kanamycin (30 mg/ml) and arabinose (0.2% w/v) as
appropriate. The zone of growth inhibition around each disc was determined, in triplicate, by taking
multiple measurements of the diameter and quoting the mean value, rounded to the nearest
integer.
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